Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The NIH announcement banner about the transition from “Artificial Intelligence” to “Super Intelligence” and related updates is no longer displayed. The page continues to show a 403 error rather than the study record.
    Difference
    1%
    Check dated 2026-11-07T11:34:01.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the study page content remains unavailable behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-31T11:25:41.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and says that “Super Intelligence” is replacing “Artificial Intelligence” in some federal agency content.
    Difference
    1%
    Check dated 2026-10-24T11:29:01.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T12:18:57.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T12:25:15.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record with a generic access-block page.
    Difference
    16%
    Check dated 2026-09-19T20:21:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.